Martín Angel· @Martin_AngelMD · X·· 14 小时前评分70
正文 · 原文
Presidential symposium 1️⃣!!
DeLLphi-305 study:
Tarlatamab + durva significantly improved ✅ OS, PFS, and ORR ‼️ in 1LM ES-SCLC @myESMO #ESMO26 a 🆕 standard of care!
51 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Martín Angel · x.com